The University of Manchester and AstraZeneca have entered into a strategic collaboration to develop cutting-edge technologies designed to enhance the way that drugs work and deliver better health outcomes for patients.
The North West Centre for Advanced Drug Delivery will be housed in Manchester Pharmacy School and will have links to a wide range of research groups throughout the University.
The centre’s remit is to deliver enhanced fundamental understanding of drug delivery systems including relevant aspects of biology and physiology in cancer and other therapeutic areas that AstraZeneca is engaged in.
The collaboration’s longer term ambition is to deliver a portfolio of advanced drug delivery technologies for use with AstraZeneca drugs.
The collaboration will run for an initial period of five years, with academic researchers and AstraZeneca scientists benefiting from their close proximity and the increased open innovation happening across the two organisations.
Astrazeneca scientists will be fully engaged in research projects, whilst University of Manchester researchers will have the opportunity to apply their science in the company’s drug development programmes.
A cornerstone of this collaboration is the creation of a manufacturing laboratory for advanced drug delivery technologies housed in the Manchester Pharmacy School.
The new centre will see world-class researchers across a range of disciplines working side-by-side with scientists in AstraZeneca’s Pharmaceutical Development group based on the Macclesfield Campus in Cheshire.
This work also complements another partnership at the Manchester Pharmacy School, where scientists from the Quantitative Clinical Pharmacology organisation at AstraZeneca have joined with academics from the School to form a Modelling and Simulation Centre.
Professor Kay Marshall, Head of Manchester Pharmacy School said: “This is a fantastic opportunity for the students and staff of the Manchester Pharmacy School. We look forward to expanding our existing research in drug delivery enabling us to consolidate further our productive relationship with AZ, for which the common aim is to improve patient care and health outcomes in areas of unmet need.”